A Phase I Trial of Continuous Infusion UCN-01 in Patients With Refractory Neoplasms
Status:
Completed
Trial end date:
2002-05-01
Target enrollment:
Participant gender:
Summary
This is a dosage escalation study to estimate the maximum tolerated dose of staurosporine
analogue UCN-01. Groups of 3 to 6 patients receive a 72-hours intravenous continuous
infusions of UCN-01 from day 1 to day 4 of each cycle the first cycle only, and over 36-hours
on subsequent cycles. The side effects are allowed to disappear for up to 28 days. This cycle
is repeated after evaluations and follow-ups, which are every 4 weeks, as long as the patient
benefits.